MA31315B1 - Utilisation d'une composition comprenant du formotérol et du beclometasone dipropionate de béclométasone pour la prévention et/ou le traitement d'une exacerbation de l'asthme - Google Patents

Utilisation d'une composition comprenant du formotérol et du beclometasone dipropionate de béclométasone pour la prévention et/ou le traitement d'une exacerbation de l'asthme

Info

Publication number
MA31315B1
MA31315B1 MA32284A MA32284A MA31315B1 MA 31315 B1 MA31315 B1 MA 31315B1 MA 32284 A MA32284 A MA 32284A MA 32284 A MA32284 A MA 32284A MA 31315 B1 MA31315 B1 MA 31315B1
Authority
MA
Morocco
Prior art keywords
beclomethasone
asthma
composition
formoterol
prevent
Prior art date
Application number
MA32284A
Other languages
Arabic (ar)
English (en)
Inventor
Paolo Chiesi
Ivano Rondelli
Daniela Acerbi
Gianluigi Poli
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38458097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31315(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA31315B1 publication Critical patent/MA31315B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur l'utilisation d'une composition comprenant une combinaison fixe a) de formotérol, d'un sel ou solvate pharmaceutiquement acceptable de celui-ci ou d'un solvate d'un tel sel; et b) de dipropionate de béclométasone. La composition sert à fabriquer un médicament pour prévenir et/ou traiter une crise d'asthme, d'asthme intermittent et/ou d'épisodes d'asthme chronique pendant la thérapie d'entretien de l'asthme ; la même composition pour servir à soulager l'asthme symptomatique, si nécessaire.
MA32284A 2007-04-19 2009-10-15 Utilisation d'une composition comprenant du formotérol et du beclometasone dipropionate de béclométasone pour la prévention et/ou le traitement d'une exacerbation de l'asthme MA31315B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07007930A EP1982709A1 (fr) 2007-04-19 2007-04-19 Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme
PCT/EP2008/003012 WO2008128685A1 (fr) 2007-04-19 2008-04-16 Utilisation d'une composition comprenant du formotérol et du dipropionate de béclométasone pour la prévention et/ou le traitement d'une crise d'asthme

Publications (1)

Publication Number Publication Date
MA31315B1 true MA31315B1 (fr) 2010-04-01

Family

ID=38458097

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32284A MA31315B1 (fr) 2007-04-19 2009-10-15 Utilisation d'une composition comprenant du formotérol et du beclometasone dipropionate de béclométasone pour la prévention et/ou le traitement d'une exacerbation de l'asthme

Country Status (30)

Country Link
US (1) US20080261932A1 (fr)
EP (3) EP1982709A1 (fr)
JP (2) JP5492072B2 (fr)
KR (3) KR101621676B1 (fr)
CN (1) CN101657191B (fr)
AU (1) AU2008241045C1 (fr)
BR (1) BRPI0809800A2 (fr)
CA (1) CA2684539A1 (fr)
CO (1) CO6220945A2 (fr)
CY (1) CY1117568T1 (fr)
DK (1) DK2146704T3 (fr)
EA (1) EA018589B1 (fr)
ES (2) ES2568497T3 (fr)
GE (1) GEP20145999B (fr)
HK (1) HK1137357A1 (fr)
HR (1) HRP20160588T1 (fr)
HU (1) HUE029263T2 (fr)
IL (1) IL201632A (fr)
MA (1) MA31315B1 (fr)
ME (1) ME00945B (fr)
MX (1) MX2009010851A (fr)
MY (1) MY169579A (fr)
NZ (1) NZ580526A (fr)
PL (2) PL2146704T3 (fr)
RS (1) RS54874B1 (fr)
SI (1) SI2146704T1 (fr)
TN (1) TN2009000390A1 (fr)
TR (1) TR201909857T4 (fr)
UA (1) UA100237C2 (fr)
WO (1) WO2008128685A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982709A1 (fr) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme
PL2482799T3 (pl) * 2009-10-02 2014-11-28 Chiesi Farm Spa Farmaceutyczne formulacje aerozolowe formoterolu i dipropionianu beklometazonu
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
MY165888A (en) 2012-01-25 2018-05-18 Chiesi Farm Spa Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
CN113069417A (zh) * 2016-09-19 2021-07-06 墨西哥氟石股份公司 药物组合物
CN107233311B (zh) * 2017-06-27 2020-12-04 长风药业股份有限公司 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法
WO2024097413A1 (fr) * 2022-11-03 2024-05-10 Dana-Farber Cancer Institute, Inc. Méthodes de traitement de l'anémie à l'aide de formotérol ou d'un sel pharmaceutiquement acceptable de celui-ci

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
HU0004452D0 (fr) 1991-12-18 2001-01-29 Astra Ab
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
AU2000250701B2 (en) 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
CN100398094C (zh) 2002-03-01 2008-07-02 奇斯药制品公司 福莫特罗超细制剂
EP1982709A1 (fr) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme

Also Published As

Publication number Publication date
EP3034073B1 (fr) 2019-06-12
SI2146704T1 (sl) 2016-05-31
NZ580526A (en) 2012-07-27
EA200901201A1 (ru) 2010-04-30
UA100237C2 (uk) 2012-12-10
TR201909857T4 (tr) 2019-07-22
EP2146704A1 (fr) 2010-01-27
CN101657191B (zh) 2014-06-11
JP2010524873A (ja) 2010-07-22
KR20150082699A (ko) 2015-07-15
RS54874B1 (sr) 2016-10-31
EP1982709A1 (fr) 2008-10-22
IL201632A0 (en) 2010-05-31
CA2684539A1 (fr) 2008-10-30
KR20150038618A (ko) 2015-04-08
MX2009010851A (es) 2009-11-05
AU2008241045C1 (en) 2023-06-15
PL2146704T3 (pl) 2016-09-30
AU2008241045B2 (en) 2013-06-20
ME00945B (fr) 2012-06-20
EP2146704B1 (fr) 2016-03-23
DK2146704T3 (en) 2016-05-23
HRP20160588T1 (hr) 2016-07-01
HK1137357A1 (en) 2010-07-30
AU2008241045A1 (en) 2008-10-30
GEP20145999B (en) 2014-01-10
CN101657191A (zh) 2010-02-24
ES2740103T3 (es) 2020-02-05
JP2014005312A (ja) 2014-01-16
US20080261932A1 (en) 2008-10-23
PL3034073T3 (pl) 2019-11-29
HUE029263T2 (en) 2017-02-28
KR20100014408A (ko) 2010-02-10
BRPI0809800A2 (pt) 2014-10-07
CY1117568T1 (el) 2017-04-26
TN2009000390A1 (en) 2010-12-31
CO6220945A2 (es) 2010-11-19
KR101668203B1 (ko) 2016-10-20
KR101621676B1 (ko) 2016-05-16
IL201632A (en) 2016-09-29
MY169579A (en) 2019-04-22
WO2008128685A1 (fr) 2008-10-30
EP3034073A1 (fr) 2016-06-22
ES2568497T3 (es) 2016-04-29
EA018589B1 (ru) 2013-09-30
JP5492072B2 (ja) 2014-05-14

Similar Documents

Publication Publication Date Title
MA31315B1 (fr) Utilisation d'une composition comprenant du formotérol et du beclometasone dipropionate de béclométasone pour la prévention et/ou le traitement d'une exacerbation de l'asthme
BRPI0409125A (pt) terapia de combinação para constipação compreendendo um laxativo e um antagonista de opióide periférico
BRPI0508251A (pt) métodos para o tratamento de tinido auditivo induzido por excitotoxicidade coclear
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
BRPI0013478B8 (pt) medicamento compreendendo inibidor pde e uso de roflumilast
NO20033862L (no) Fremgangsmåte for prevensjon eller terapi av inflammatoriske eller autoimmune lidelser ved administrering av integrin-alfa-beta3-antagonisteri kombinasjonmed andre profylaktiske eller terapeutiske midler
TW200731968A (en) Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
HUP0103108A2 (hu) Formoterolt és budesonidot tartalmazó készítmény alkalmazása asztma akut állapotának megelőzésére
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
MA32462B1 (fr) Dronedarone dans le traitement prophylactique de la fibrillation auriculaire permanente
WO2003065987A3 (fr) Inhibiteurs de granzyme b
DK1778709T3 (da) Polysulfaterede glykosider og salte deraf
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
Kim Deep vein thrombosis prophylaxis after total hip arthroplasty in Asian patients
CA2364178A1 (fr) N-benzenesulfonyl-l-prolines utilisees comme antagonistes de la bradykinine
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
SE0300445D0 (sv) New combination
WO2003015690A3 (fr) Methode de traitement de l'insomnie primaire
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
NO20041595L (no) Ny kombinasjon bestaende av en PDE4 inhibitor eller en PDE3/4 inhibitor i kombinasjon med en leukotrienreseptorantagonist for behandling av luftveislidelser
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
DE60014429D1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
EP4140479A4 (fr) Agent thérapeutique et/ou préventif pour la maladie à coronavirus 2019 (covid-19)
WO2001021167A8 (fr) Traitement des symptomes des voies urinaires basses, et compositions pharmaceutiques a utiliser dans le cadre dudit traitement